MagnetisMM-1: A study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM) Meeting Abstract
| Authors: | Levy, M.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; Basu, C.; Skoura, A.; Chan, E.; Trudel, S.; Jakubowiak, A.; Chu, M.; Gasparetto, C.; Dalovisio, A.; Sebag, M.; Lesokhin, A. |
| Abstract Title: | MagnetisMM-1: A study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM) |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | multiple myeloma; immunotherapy; mm; bcma; elranatamab |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S439 |
| Language: | English |
| ACCESSION: | WOS:000691910500416 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01978-9 |
| Notes: | Meeting Abstract: MM-379 -- Source: Wos |
